SRPT: sarepta.com Company Total Sales

sarepta.com - graphic logo of issuer SRPT

Sarepta Therapeutics, Inc. (SRPT) generates revenue from exclusive RNA-based drugs protected by complex patents and orphan drug status. The company's commercial sales volume, as shown on this GURU.Markets chart, confirms revenue growth, where the value 1.96 reflects the metric's balance. Current success is based on the expansion of insurance reimbursements, which has allowed the company to optimize R&D costs and stabilize operational activities.

Sarepta (SRPT) - Revenue and Sales Volume from 07/04/2022 to 11/18/2026

Comprehensive metric breakdowns and analytics for Sarepta Therapeutics (SRPT)

- share price and expert price forecast:
Comprehensive company analysis:Sarepta Therapeutics, Inc. (SRPT)
Flagship merchandise of Sarepta

This aggregate sales figure confirms the status of Sarepta Therapeutics, Inc. (SRPT) as a leader in the therapy of rare muscle pathologies. The metric captures actual cash flow, reflecting the dynamics of consumer demand for the drugs. Rising values indicate effective business scaling and an expansion of market share. Dominance in the treatment of Duchenne muscular dystrophy allows the issuer to maintain high pricing power. This ensures the stability of fundamental positions during shifts in market trends.

Key competitors

Tempus AI, Inc. (TEM) - Company Gross Revenue|Company Sales QGEN (Qiagen NV)|Revenue and Sales Volume Ionis Pharmaceuticals, Inc. (IONS)|Revenue and Sales Volume RGEN (Repligen Inc.)|Avidity Corp (RNA) - Company Total Revenue|CRSP - Company Revenue|Company Gross Revenue genedx.com WGS|Ultragenyx Pharmaceutical (RARE) - Company Revenue|Company Total Revenue Beam Therapeutics Corp (BEAM)|TWST (twistbioscience.com) - Revenue and Sales Volume|Company Sales Volume TXG (10x Genomics Corp)|Revenue and Sales Volume NTLA|Revenue and Sales Volume Stoke Therapeutics, Inc. (STOK)|Company Revenue BioLife BLFS|WVE - Company Sales|Maze Therapeutics Corp - Revenue and Sales Volume|Sionna Pharma - Company Total Sales|Prime Medicine (PRME) - Company Revenue|tayshagtx.com (TSHA) - Revenue and Sales Volume|Company Revenue uniQure Corp|MGTX: Company Sales Revenue|Revenue and Sales Volume RGNX|Company Gross Revenue Solid Corp|Revenue and Sales Volume OCGN (ocugen.com)|PACB (Pacific Biosciences) - Company Annual Revenue|Benitec Biopharma Inc - Revenue and Sales Volume|Company Gross Revenue Design Therapeutics, Inc. DSGN|Rocket Corp (RCKT) - Company Revenue|4D Molecular Therapeutics (FDMT) - Revenue and Sales Volume|LXEO (Lexeo Therapeutics, Inc.) - Revenue and Sales Volume|Company Total Revenue korrobio.com KRRO|Company Sales EDIT (Editas Medicine, Inc.)|Silence Therapeutics plc - Company Sales Volume|Company Revenue ProQR Therapeutics N.V. PRQR|Company Gross Revenue Codexis, Inc. (CDXS)|SGMO - Company Revenue|nautilus.bio - Company Total Sales|Metagenomi, Inc (MGX) - Company Revenue|Company Sales Volume DTIL|Company Revenue Generation Bio|Revenue and Sales Volume Boundless Bio Inc|Company Revenue Exicure Corp (XCUR)|Company Gross Revenue Imunon|Revenue and Sales Volume PHIO (phiopharma.com)|Company Total Sales Volume mustangbio.com|RNAZ - Company Revenue|Company Total Revenue Bionano Genomics|APDN: Revenue and Sales Volume|Company Sales Volume BLUE|Company Sales IPA|OMGA: Company Sales Revenue|Revenue and Sales Volume OMIC|Company Gross Revenue Regulus Therapeutics|Company Revenue Syros SYRS|Company Sales Revenue TBIO|TCON: Company Sales|Unity Biotechnology, Inc. (UBX) - Company Sales